A series of papers have found evidence for the relevance of NF-κB in RA [27, 28], and the degree to which it is inhibited by CIE has been identified as an indicator of CIE's promise as therapeutic agent. The gene discussed is NFKB1; the disease is rheumatoid arthritis.